The DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index.
Tools for translation: non-viral materials for therapeutic mRNA delivery
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To maximize translation, the mRNA sequence typically incorporates modified nucleosides, such as pseudouridine, N1-methylpseudouridine or other nucleoside analogues23.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [23]
In the citing paper
“mRNA has shown therapeutic potential in a range of applications, including viral vaccines, protein replacement therapies, cancer immunotherapies, cellular reprogramming and genome editing2,4,7–17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“These lipids can improve nanoparticle properties, such as particle stability, delivery efficacy, tolerability and biodistribution7,14,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“Trapped in endosomes, in which the pH is lower than in the extracellular environment, ionizable lipids are protonated and, therefore, become positively charged, which may promote membrane destabilization and facilitate endosomal escape of the nanoparticles7,11,14”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“To function in vivo, lipid nanoparticle–mRNA formulations need to overcome multiple extracellular and intracellular barriers7,11 (Fig. 3a).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“In addition to cationic or ionizable lipids, lipid nanoparticle–mRNA formulations typically contain other lipid components, such as phospholipids (for example, phosphatidylcholine and phosphatidylethanolamine), cholesterol or polyethylene glycol (PEG)-functionalized lipids (PEG-lipids)7,14,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“The pH-sensitivity of ionizable lipids is beneficial for mRNA delivery in vivo, because neutral lipids have less interactions with the anionic membranes of blood cells and, thus, improve the biocompatibility of lipid nanoparticles7,11,14.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“mRNA normally contains five structural elements, that is, a 5′ cap, a 3′ poly(A) tail, a protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“These elements can be engineered to improve the stability and translational efficiency of mRNA2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“Chemical modifications of specific IVT mRNA nucleotides, such as pseudouridine (ψ) and N1-methylpseudouridine (m1ψ), can reduce innate immune sensing of exogenous mRNA translation2,4,7,182.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“Chromatographic purification can remove double-stranded RNA, an analogue of viral genome, in IVT mRNA preparations, diminishing immune activation and increasing translational efficiency2,4,7,183.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“To address these concerns, the engineering of mRNA molecules (Box 1) and the design of lipid nanoparticles have been optimized2,4,7–17, which has contributed to the rapid development and clinical assessment15,17 of the two COVID-19 mRNA vaccines, mRNA-1273 (NCT04470427)19,20 and BNT162b2 (NCT04368728)21.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“Polymers, such as polyethyleneimine, protamine and polyaspartamide derivatives, are already widely used for mRNA delivery7–17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“mRNA functions as the bridge between DNA and proteins in eukaryotic cells.[8, 12, 119]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Polyethylenimine (PEI) is one of the most developed cationic polymers [39], but its toxicity has limited the therapeutic applications.[8, 124]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Compared with protein drugs, mRNA can supplement both cytoplasmic and large transmembranic proteins.[8, 119, 120]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Recently, many biomaterials have been developed for mRNA delivery, including lipids and lipid derived materials, polymers, and many others. [8, 39, 120, 124]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Relative to plasmid DNA (pDNA), mRNA possesses temporary bioactivity and functions outside the nucleus, leading to a more controllable protein expression and avoiding the potential insertion of the genome.[8, 119, 120]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“For many GARDs, the liver is a preferred organ for mRNA-based PRTs because systemically administrated mRNA vehicles are predominantly trapped by the reticuloendothelial system (RES) in the liver.”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“In addition, the interaction between apolipoprotein E (apoE) and biomaterials such as lipid and lipid derived materials facilitates the accumulation in the liver.[8, 18, 34, 39, 59, 120, 121, 124, 164, 165]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Meanwhile, ionizable lipid and lipid derived materials, which acquire positive charges at low pH and become neutral at physiological pH, have been developed for decreasing the toxicity and immunogenicity while retaining the delivery efficiency.[8]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Boussif, O., Lezoualc’h, F., Zanta, M. A., Djavaheri‐Mergny, M., Scherman, D., DEMENEIX, B. A., & Behr, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,256
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Research works printed but not linked: 1
- Moderna Therapeutics. Moderna Provides Pipeline and Full-Year Corporate Update. Moderna [online], https://www.modernatx.com/newsroom/press-releases/moderna-provides-pipeline-and-full-year-corporate-update (2017).
Cited by
Sorted by citations
Items 701–799 of 799
Sun, Y., Kunanusorn, P., Tup, K. M., Chokkakula, S., & Yang, B. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1859541 · Cited by 1
POTENTIAL THERAPEUTIC EFFECT OF ZIKA VIRUS IN GLIOBLASTOMA TREATMENT
do Nascimento, S. I. B., dos Santos, S. T. L., Alves, B. T., Aguilera, K. C., de Menezes, A. C. P., Alencar, A. M. C., de Andrade, A. M. L. C., Leite, D. G., & de Melo, A. M. D. (2018) · Amadeus International Multidisciplinary Journal · doi:10.14295/aimj.v2i4.36 · Cited by 1
Strategies and Advances in Tumor Immunotherapy
Luo, J. (2020) · Materials science forum · doi:10.4028/www.scientific.net/msf.1009.15 · Cited by 1
Recent development in the pharmaceutical industries
Poonia, E., Ranga, N., Ranga, R., & Kumar, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95325-2.00017-1 · Cited by 1
Applications of Spray-Dried Vaccines
Arpagaus, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-24323-3_6 · Cited by 2
The development and technologies of RNA therapeutics
Vuong, H. L., Lan, C. T., & Le, H. T. T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.017 · Cited by 1
Self-assembled structures as emerging cellular scaffolds
Gaur, D., Dubey, N. C., & Tripathi, B. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99472-9.00023-7 · Cited by 1
Vaccine Nanotechnology for the Prevention of Infectious Diseases
Sontakke, S., Sharma, P. C., Worsham, R., Kadur, K., Bhargavi, C., & Morebise, O. (2023) · Springer eBooks · doi:10.1007/978-3-031-49933-3_4 · Cited by 1
Wang, Y., Zhang, M., Li, G., Hou, T., Li, Z., Chen, S., Wang, D., & Jiang, W. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1077 · Cited by 2
COVID-19 and progress in therapeutic approaches: a narrative review
Ilyas, U., Jadoon, S. S., Ahmed, T., Altaf, R., Khan, A., Ahmad, A., Rasool, Y., Masaud, S. M., & Khan, Z. (2024) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.1394329 · Cited by 1
Application of quantitative and engineering biology in mRNA gene therapy
Xiang, H., Ke, L., Yang, X., Guo, J., Yang, W., & Hu, Y. (2020) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2020-0476 · Cited by 1
mRNA Structuring for Stabilizing mRNA Nanocarriers and Improving Their Delivery Efficiency
Uchida, S., Koji, K., Yoshinaga, N., Mochida, Y., Hong, T., & Cabral, H. (2020) · International Online Conference on Nanomaterials (IOCN) · doi:10.3390/iocn2020-07789 · Cited by 1
Delivery strategies for reprogramming tumor-associated macrophages
Ramesh, A., & Kulkarni, A. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00004-x · Cited by 1
Gill, K., Minall, L., & Nassif, A. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814357-5.00007-6 · Cited by 1
mRNA Vaccine: Determinants of Clinical Efficacy, and Optimization of Pharmacological Effects
Ohanube, G. A. K., & Obeta, U. M. (2021) · International Journal of Pharmaceutical and Phytopharmacological Research · doi:10.51847/175q0zatao · Cited by 1
Safe and efficient RNA and DNA introduction into cells using digital electroporation system
Bae, S. J., & Im, D. J. (2022) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2022.108268 · Cited by 1
Nanoparticle‐Based mRNA Vaccines
Nalla, L. V., Gajula, S. N. R., & Chavda, V. P. (2024) · Wiley eBooks · doi:10.1002/9781394175482.ch8 · Cited by 1
Palanikumar, L., Yasin, F. M., Munkhjargal, I., Boitet, M., Ali, L., Ali, M. E. M., Straubinger, R., Barrera, F. N., & Magzoub, M. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.20.639217 · Cited by 1
Stretchable, hair-compatible, and long-term stable wearable EEG systemPreprint
Hsieh, J.-C., Yao, M., Alawieh, H., Koptelova, V., Kumar, S., Tang, K. W. K., Wang, W., Jeong, J., Ding, H. Q., Chae, T. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.28.651043 · Cited by 1
Ikrar, T., Muchsin, W., & Sophian, A. (2026) · Research Square · doi:10.21203/rs.3.rs-9109248/v1 · Cited by 1
Gene Therapy for Neuroanesthesia
Hauck, E. S., & Hecker, J. G. (2019) · Springer eBooks · doi:10.1007/978-981-13-3387-3_37
Therapeutic applications of siRNA gene delivery systems
Madkour, L. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819777-6.00005-6 · Cited by 2
Moura Paiva, I. (2020) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-5141-r867
Designed synthesis of silica based nanocarriers for mRNA delivery
Wang, Y. (2020) · The University of Queensland · doi:10.14264/b28d1e7
COMO ANDA A SITUAÇÃO DA PANDEMIA NO BRASIL E NO MUNDO?
Marques, C. C. D. G., Marques, M. L. D. G., Reis, S. P., Romano, R. G., Figueiredo, L. C., Marques, K. S., & de Oliveira, M. C. B. (2021) · doi:10.22533/at.ed.5312117069
Andrade, P. A., Melo, L. U., da Silva, F. W. C., dos Santos, A. N., Brito, N. S., Miranda, K. C. L., Machado, L. D. S., & Xavier, S. P. L. (2021) · doi:10.22533/at.ed.53121170612
IMPACTOS DA PANDEMIA DE COVID-19 NA SAÚDE MENTAL DE JOVENS UNIVERSITÁRIOS
Silveira, A. D. O., Soccol, K. L. S., Huppes, G. M., Soster, F. F., de Oliveira, J. P., & Bueno, T. D. V. (2021) · doi:10.22533/at.ed.53121170615
ALIMENTOS DESIDRATADOS: SABOR, SAÚDE e IMUNIDADE EM TEMPOS DE QUARENTENA
Galvão, A. B., dos Anjos, A. M. P., Soares, A. D. A., Costa, P. D. S., Furtado, P. V. O. S., Silva, I. K. D. C., & Felipe, M. G. (2021) · doi:10.22533/at.ed.5312117062
He, X. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738957376.793579986
Platform Technologies for Improving in vivo Functionalities of mRNA Therapeutics
Uchida, S. (2021) · Journal of the Society of Powder Technology Japan · doi:10.4164/sptj.58.627
Gaucherel, C., Gouyon, P., & Dessalles, J.-L. (2018) · doi:10.1002/9781119579373.refs
mRNA AŞILARINDA GÜNCEL YAKLAŞIMLAR
BATUR, K., & Yardımcı, H. (2022) · Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni · doi:10.38137/vftd.1021843
Non-viral gene editing in utero with lipid nanoparticles complexed to mRNAPreprint
Gao, K., Li, J., Song, H., Han, H., Wang, Y., Yin, B., Farmer, D. L., Murthy, N., & Wang, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.14.512310
“The in utero transfection levels in utero were similar between the heart, lung, liver, kidneys, GI tract, presumably due to diffusion into the vasculature of multiple organs simultaneously, in contrast, intravenous injection of LNPs in adults generates predominantly transfection in the liver [34].”
Backgroundda Silva, J. R. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2021.tde-17032022-102622
Messenger RNA Nanovaccine in Cancer Immunotherapy
Li, M., & Zhang, H. (2022) · Springer eBooks · doi:10.1007/978-3-031-17831-3_9
Nanomaterials for Therapeutic Nucleic Acid Delivery
Du, S., Cheng, J. K. J., & Dong, Y. (2022) · Springer eBooks · doi:10.1007/978-981-16-1313-5_100-1
Vaccines and Neglected Tropical Diseases: a complicated challenge or a postpandemic hope
Diego, J. G.-B., Manzano-Román, R., & Muro, A. (2022) · Anales de la Real Academia Nacional de Farmacia · doi:10.53519/analesranf.2022.88.05.22
Touramanidou, L., Gurung, S., Cozmescu, A. C., Perocheau, D. P. B., MOULDING, D. A., Ridout, D. A., Cavedon, A., Siddiqui, S., Rice, L. M., Finn, P. F., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.26.550697
“, lipid nanoparticles (LNP) 83 encapsulating mRNA (LNP-mRNA) [22-27] respectively.”
BackgroundHuman β-Defensin 23 as a Carrier for In Vitro and In Vivo Delivery of mRNA
Kim, K., Kim, J., Cho, S., & Ahn, D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102477
Aliakbarinodehi, N., Niederkofler, S., Olsén, E., Jing, Y., Emilsson, G., Sjöberg, M., Agnarsson, B., Lindfors, L., & Höök, F. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.22.580934
THE SCIENCE OF HOPE: A COMPREHENSIVE REVIEW OF COVID-19 VACCINE PROGRESS
Srivastava, A., Chaturvedi, V., Wal, P., Srivastava, P., Wal, A., & Yadav, A. (2022) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/jptcp.v29i04.4383
Skelton, A. M., DeMoya, C. D., Cohen, D. J., Kirsch, J. R., Beaudry, P., Boyan, B. D., Grinstaff, M. W., & Schwartz, Z. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4797381
RNA Temelli Terapötik Yaklaşımlar
Korkmaz, İ., & Arslan, S. (2024) · Uludağ Üniversitesi Tıp Fakültesi Dergisi · doi:10.32708/uutfd.1427446
Gene Expression and Editing in Mammalian Retinal Ganglion Cells
Tran, N. M., Xu, X., Qi, L. S., & Hu, Y. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_19
Engineering of mRNA vaccine platform with reduced lipids and enhanced efficacyPreprint
Ji, T., Ma, X., Liu, S., Zhang, S., Liu, Z., Wang, H., Luo, W., Zu, M., Qin, H., Li, Z., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4755456/v1
Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00004-2
Further therapeutic applications of mRNA and saRNA
Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00007-8 · Cited by 1
Xu, W., & Wang, C. (2024) · International Conference on Biomedical Engineering and Applications (ICBEA) · doi:10.1109/icbea62825.2024.00049
mRNA vaccines: the next frontier in disease prevention
Babar, Q. A., Maryam, M., MUHAMMAD, A. M., Tahir, M. F., & Ali, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00016-9
Николаевна, Р. М., Levina, A. S., Mazurkov, O. Y., Makarevich, E. V., Filippova, E. I., Mazurkova, N. A., & Zarytova, V. F. (2024) · Journal of microbiology epidemiology immunobiology · doi:10.36233/0372-9311-575
Editorial: Structure-function relationship of enzymes through a chemical lens
Miller, J. M., & Offenbacher, A. R. (2025) · Frontiers in Chemical Biology · doi:10.3389/fchbi.2025.1565931
Research Progress on mRNA Based Protein Replacement Therapy for Inborn Errors of Metabolism
李, 京. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.154899
One‐Component Ionizable Amphiphilic Janus Dendrimers for Targeted mRNA Delivery
Zhu, P., Li, Y., & Zhang, D. (2025) · Angewandte Chemie · doi:10.1002/ange.202505304
Gao, D., Xu, Z., Li, X., Zhao, Y., Min, Q., Chen, Z., Xu, Q. H., Tian, Y., Xu, J., & Zhu, J. (2025) · Angewandte Chemie · doi:10.1002/ange.202505290
Nano-delivery Systems for mRNA: A comprehensive review of lipid-based and polymer-based approaches
Turankar, C. C., Kubde, J. A., Hatwar, P. R., Bakal, R. L., & Mahure, L. D. (2025) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2025.23.1.0107 · Cited by 1
“Most human proteins undergo post-translational modification in the Golgi apparatus and endoplasmic reticulum to achieve full functioning [13] . mRNA-loaded LNP could be improved to more accurately deliver the mRNAs to a particular cell, tissue or organ, increasing its effectiveness and lowering its…”
RNA in the Central Dogma: mRNA
Saw, P. E., & Song, E. (2025) · Springer eBooks · doi:10.1007/978-981-96-3041-7_3
Maltodextrin-modified lipoplexes for enhanced mucosal penetration and efficient mRNA delivery
Kopilovic, B., Laroui, N., Berchel, M., Jaffrès, P., Midoux, P., Freire, M. G., & Pichon, C. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101975
Bozza, A., Beraza-Millor, M., Rodríguez-Castejón, J., Arratia, F. A. S., Cavalli, R., Camisassa, E., Muntoni, E., Marengo, A., Valsania, M. C., del Pozo‐Rodríguez, A., et al. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114795
Shankar, D., Mishra, D. K., Singh, A., Pathak, N., Minocha, N., Pandey, P., & Malhotra, P. (2025) · Current Nanomedicine · doi:10.2174/0124681873339647250214070805
BIOCOMPATIBILITY OF LARGE-AREA 2-DIMENSIONAL ELECTRONIC MATERIALS WITH NEURAL STEM CELLSPreprint
Jayanth, R., Duquette, R. D., Kutagulla, S., Salazar, S. P., Okogbue, E., Zhou, J., Jung, Y., Duan, X., Kireev, D., Seidlits, S. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.19.665698
Saraf, S., Tiwari, A., Panda, P. K., Jain, A., & Jain, S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107458
Nanotechnology-based CAR strategies for tumor immunotherapy
Adabi, M., Esmaeili, Z., Esnaashari, S. S., Taleb, M., Khosravani, M., & Adabi, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21521-6.00006-5
Tissue targeting approaches for drug delivery
Zhang, D., Su, D., Alicea-Salas, J. Y., Zang, R., & Wright, M. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00049-2
Polycation-based miRNA delivery system for choroidal neovascularization treatment
Cao, Q., Yu, L., Xia, W., Guo, A., Jiang, M., Yang, L., Dong, Q., Zheng, W., Yao, Y., Zhang, S., et al. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112031
Awakening Sleeping Beauties from articles on mRNA vaccines against COVID-19
Chaleplioglou, A., Selinopoulou, E., Kyprianos, K., & Koulouris, A. (2026) · Scientometrics · doi:10.1007/s11192-026-05598-x · Cited by 1
Engineering bone tissue with mRNA: from molecular design and delivery to clinical applications
Runzer, C. D. T., van Griensven, M., & Balmayor, E. R. (2025) · Materials Today · doi:10.1016/j.mattod.2025.11.002 · Cited by 1
Yang, N., Zhang, C., Zhang, Y., Fan, Y., Zhang, J., Lin, X., Guo, T., Gu, Y., Wu, J., Gao, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25397502
Kumari, M., Lu, R.-M., Li, M.-C., Huang, J., Hsu, F.-F., Ko, S.-H., Ke, F.-Y., Su, S.-C., Liang, K.-H., Yuan, J. P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21085242
Nanoimmunotherapy and nanomedicine
Rahvar, M., Gholami, L., & Rahmani, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21521-6.00004-1
Chen, Z., Yang, J., Zheng, B., Yang, Y., Qiu, X., Zhou, H., Wang, R., & Xiong, H. (2026) · Angewandte Chemie · doi:10.1002/ange.202523579
Future trends in LNP-mRNA therapeutics
Singh, A. K., Singh, B., & Mishra, S. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00014-8
Zhang, X., Liao, Y., Hong, X., Xiao, Y., & Zeng, X. (2026) · Science China Chemistry · doi:10.1007/s11426-025-3182-6
Lambart, I., Flender, D., Liu, D., Hoang, J. H., Hesse, M., Campillo-Davó, D., Lion, E., Audenaerde, J. R. M. V., Schiller, S., Simon, J., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040403
“Two recent reviews described how a variety of LNP formulations has been investigated for the transfection of immune cells [26,27], important for starting the immune response generation after administration of mRNA vaccines [35].”
Niazi, S. (2026) · Drug Design, Development and Therapy · doi:10.2147/dddt.s576169
Zhang, Z., Chen, Z., Lu, Y., Li, N., Zhang, Q., Liu, T., Tong, X., Qu, J., Gao, H., & Li, Z. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107526
Multifunctional nanocomposites for precise control over drug delivery
Andretto, V. (2022) · theses.fr (ABES) · doi:10.70675/7a7f57fez25f2z41a0z9072z3f3cc2aef2d6
Research progress and challenges in in vivo CAR-T cell therapy
HUANG, Y.-F., & Zhang, Y. (2026) · Shengming kexue · doi:10.3724/cbls.2026074
Arral, M. L., Chaudhary, N., Fein, K. C., Newby, A. N., Yerneni, S. S., Melamed, J. R., LoPresti, S. T., Petersen, D. M. S., & Whitehead, K. A. (2026) · Drug Delivery and Translational Research · doi:10.21203/rs.3.rs-9763025/v1 · Cited by 1
“Because mRNA expression is transient, repeated administration is typically required for therapeutic effect[25].”
Self-citationCurrent progress in developing mRNA-lipid nanoparticle vaccines against human bacterial pathogens
Pullinger, B., Harbison-Price, N., Sebina, I., Na, J., Belz, G. T., & Walker, M. J. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00138-26
Zhang, L., (24124354), Y. G., Hu, Z. W., Chen, Y., Wu, C., Shuai, Q., & Yan, Y. (2026) · Macromolecular Bioscience · doi:10.1002/mabi.70220
Stabilizing Anionic mRNA Lipid Nanoparticles by Cleavable Crosslinking of Cholesterol
Su, Y., Choy, J., Liu, X., Zhu, Y., Lin, J., Wei, C., Goodier, K. D., Yu, D. S., Cheng, L., Patel, M., et al. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c06888
Coacervate-based materials as emerging vehicles for drug delivery
Xu, Y., Zhu, H., Moyle, P. M., & Wan, Y. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.07.039
“Strategies such as cell-penetrating peptides 101 , cell-penetrating poly (disulfide)s 102 , fluorinated modifications 103 , fusogenic liposomes 104 , gemini amphiphiles 105 , viral vectors 106 and a range of synthetic delivery systems 107 have been explored.”
RNA Size and Structure Modulate the Apparent p K a of Ionizable Lipid Nanoparticles
Priss, A., Lytvynenko, O., Vaněk, V., Sedlák, F., Šašková, K. G., & Cígler, P. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00177 · Cited by 1
Wang, X., Tian, Z., Benitez, A. P., Bian, X., Vaidya, A., Guerrero, E. D., Sun, Y., Zhang, C., Duan, Y., Wei, J., et al. (2026) · Nature Chemical Engineering · doi:10.1038/s44286-026-00425-9 · Cited by 2
“https://doi.org/10.1038/s44286-026-00425-9 offer unique physicochemical properties 3,28–30 and have broader space to be engineered for precise control over, for example, molecular architecture, functionality, charge, hydrophobicity and size, providing modularity and tunability to meet the complex…”
InfluentialIn vivo CAR T-cell generation: delivery platforms, clinical progress, and translational barriers
Huo, T., Yao, H., & Kong, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1927594
“Compared with viral vectors, LNPs offer greater engineering fl exibility — including surface modi fi cation for T-cell targeting — along with improved safety, lower production costs and superior scalability (74, 75).”
Nkosi, T., Molefe, L., Dlamini, S., Mokoena, A., & Ndlovu, K. (2026) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/l252254324
Petrova, E., Georgiev, I., Stoyanov, N., & Kolev, P. (2026) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/a787099787
Shao, B., Chen, M., You, C., Zhang, L., Liang, T., Zhang, G., Cen, J., Tan, J., & Liu, S. (2026) · Small · doi:10.1002/smll.75877
Singh, R. D., Calvoli, M., & Kim, K. K. (2026) · Advanced Science · doi:10.1002/advs.77370
“The rational design of LNPs for the efficient delivery of drugs in vivo includes the choice of lipids with cationic or ionizable heads, lipids functionalized with cholesterol or polyethylene glycol (PEG), lipids containing phospholipids, etc [ 175, 179 ].”
Nonviral nucleic acid delivery systems: specific features of polymeric carriers
Shaputkin, E. D., Nifant'ev, I. E., & Ivchenko, P. V. (2026) · Russian Chemical Reviews · doi:10.59761/rcr5222
Synthesis and optimization of ionizable lipids for RNA delivery
Wu, B., Lu, X., Padilla, M. S., Dharmesh, E., Xu, Y., Mitchell, M. J., & Han, X. (2026) · Chem · doi:10.1016/j.chempr.2026.103244
Maharjan, R., Kim, G. N., Jung, H. S., Kim, H. J., Kim, J.-H., Kang, H. M., Kim, H. U., & Jeong, S. H. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127476
Samadi, F. Y., Farab, M., Emadi, M., Niknam, M. R., Yousefi, M., & Minai‐Tehrani, A. (2026) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2026.100825
“56,57 Furthermore, nanoparticles possessing a net positive (cationic) charge have been reported to be particularly suitable in various biomedical applications, including siRNA condensation, drug loading, and the delivery of diagnostic or therapeutic probes.”
Bioengineering strategies for improving the immunogenicity of mRNA vaccines
Wang, H., Zhuo, R., Wu, J., & Ouyang, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02991-z
Karim, M. E., Holl, M. M. B., Corrie, S. R., & Chowdhury, E. H. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01085-w
Kaknale, S., Ranjan, A., Enoch, I. V. M. V., Vyas, A., & Manikantan, V. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12916-2
Metadata
- Authors
- Hajj, K. A., & Whitehead, K. A.
- Affiliations
- Carnegie Mellon University (US)
- Corresponding author
- Whitehead, Kathryn A.
- Venue
- Nature Reviews Materials
- Published
- 2017-09-12
- Volume
- 2
- Issue
- 10
- ISSN
- 2058-8437 (ISSN-L)
- OpenAlex
- W2754401101
- Cited by
- 799
- References
- 166
- Citations by year
- 2026: 61 · 2025: 122 · 2024: 110 · 2023: 126 · 2022: 124 · 2021: 101 · 2020: 82 · 2019: 40 · 2018: 32 · 2017: 1
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Reviews Materials (publishedVersion)
- Funders
- Defense Advanced Research Projects Agency (D16AP00143)
- Advanced Research Projects Agency
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- mRNA therapeutics, mRNA delivery, synthetic materials, lipid nanoparticles, mRNA vaccines, cancer immunotherapy, in vitro transcribed mRNA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
